A systematic review and meta-analysis suggests the dual pathway-targeting faricimab provides some greater benefit in outcomes like CST at fewer injections and without compromise of safety to anti-VEGF monotherapies.
ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
With the recent rise in the number of pharyngitis patients and fever clinic visits, experts noted that the public should take precautions, as the large increase in holiday travel may lead to a low-level outbreak during the upcoming eight-day Mid-Autumn Festival and National Day holidays.